University of Texas at Austin
utexas.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
323
Active
78
Phase 3
9
Total enrollment
53,256
Pipeline matrix
Showing 9 of 9 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lumateperone 42 mg | — | — | — | — | — | 1 | |
| Suzetrigine | — | — | — | — | — | 1 | |
| Gabapentin Enacarbil | — | — | — | — | — | 1 | |
| Sertraline | — | — | — | — | — | 1 | |
| Anticoagulants | — | — | — | — | — | 1 | |
| Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Low-dose psilocybin | — | — | — | — | — | 1 | |
| Brain state-dependent paired corticomotoneuronal stimulation | — | — | — | — | — | 1 |
Next readouts
- 2022-08-31
- 2025-04-01
- 2026-12
- 2027-07-15
- 2028-02
- 2029-12-31
- 2030-01
- 2030-07
Top conditions
- Depression20
- Healthy9
- Anxiety9
- Metabolic Syndrome7
- Major Depressive Disorder7
- Atherosclerosis5
- Obesity5
- Anxiety Disorders5
Frequently asked questions about University of Texas at Austin
- How many clinical trials does University of Texas at Austin have on ClinicalTrials.gov?
- University of Texas at Austin is listed as the lead sponsor on 323 clinical trials in ClinicalTrials.gov, 78 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Texas at Austin's trials are in Phase 3?
- 9 of University of Texas at Austin's trials are in Phase 3, spread across 9 active drug programs.
- What therapeutic areas does University of Texas at Austin focus on?
- University of Texas at Austin's most-studied conditions on ClinicalTrials.gov are Depression, Healthy, Anxiety, Metabolic Syndrome, Major Depressive Disorder.
- When are University of Texas at Austin's next clinical trial readouts?
- University of Texas at Austin has 8 upcoming primary-completion readouts tracked here; the soonest is “Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease”, expected around 2022-08-31.